State Of Wyoming Ascendis Pharma A/S Transaction History

State Of Wyoming

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 19, 2025	BUY	$137.41 - $179.1 $9,618 - $12,537	70 New	70 $12,000
Q2 2022 Aug 15, 2022	BUY	$78.08 - $117.61 $11,946 - $17,994	153 Added 52.22%	446 $41,000
Q1 2022 May 13, 2022	SELL	$102.18 - $135.75 $6,539 - $8,688	-64 Reduced 17.93%	293 $34,000
Q4 2021 Feb 11, 2022	BUY	$127.1 - $169.66 $6,863 - $9,161	54 Added 17.82%	357 $48,000
Q3 2021 Feb 11, 2022	SELL	$112.67 - $176.92 $21,294 - $33,437	-189 Reduced 38.41%	303 $48,000

Q2 2021 Feb 11, 2022	BUY	$121.62 - $145.29 $35,148 - $41,988	289 Added 142.36%	492 $65,000
Q1 2021 Feb 08, 2022	BUY	$124.92 - $173.33 $25,358 - $35,185	203 New	203 $26,000

313

65.2M

476K

142K

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $11.4B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

Get notified when there are updates to the investment portfolio of State Of Wyoming, based on Form 13F filings with the SEC.

Stay updated on State Of Wyoming with notifications on news.